News headlines about Orthofix International (NASDAQ:OFIX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Orthofix International earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news stories about the medical device company an impact score of 46.514007204985 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.
Here are some of the news stories that may have effected Accern’s rankings:
- Analyzing LDR (LDRH) & Orthofix International (OFIX) (americanbankingnews.com)
- Orthofix Int’l (OFIX) Announces FDA and CE Mark Approvals for New PhysioStim Bone Growth Stimulators (streetinsider.com)
- Orthofix PhysioStim’s FDA Nod and CE Mark Boosts Prospects (finance.yahoo.com)
- Orthofix PhysioStim's FDA Nod and CE Mark Boosts Prospects (finance.yahoo.com)
A number of equities research analysts have commented on OFIX shares. SunTrust Banks increased their target price on Orthofix International to $67.00 and gave the company a “buy” rating in a report on Monday, March 5th. ValuEngine upgraded Orthofix International from a “hold” rating to a “buy” rating in a report on Thursday, March 1st. Gabelli restated a “buy” rating on shares of Orthofix International in a report on Wednesday, February 28th. Finally, BidaskClub upgraded Orthofix International from a “sell” rating to a “hold” rating in a report on Thursday, December 21st. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $57.42.
Orthofix International (NASDAQ:OFIX) last released its quarterly earnings data on Monday, February 26th. The medical device company reported $0.52 EPS for the quarter, beating the consensus estimate of $0.50 by $0.02. Orthofix International had a return on equity of 10.66% and a net margin of 1.43%. The company had revenue of $116.90 million for the quarter, compared to analyst estimates of $116.93 million. During the same period last year, the company posted $0.42 earnings per share. The firm’s revenue was up 7.7% compared to the same quarter last year. equities research analysts anticipate that Orthofix International will post 1.82 EPS for the current fiscal year.
Orthofix International Company Profile
Orthofix International N.V. (Orthofix) is a global medical device company. The Company is focused on providing reconstructive and regenerative orthopedic and spine solutions to physicians. The company operates in four segments: BioStim, Biologics, Extremity Fixation and Spine Fixation. Its BioStim solutions products include Cervical-Stim, Spinal-Stim and Physio-Stim.
Receive News & Ratings for Orthofix International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orthofix International and related companies with MarketBeat.com's FREE daily email newsletter.